Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-224 pembrolizumab monotherapy in advanced hepatocellular carcinoma
2015-004566-28Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Merck & Co. Primary endpoint: Overall response rate. Started Mar 2016; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2015-004566-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004566-28.